Clinical Report: Correction in Methodology

Overview

This report addresses a correction in the methodology of a randomized clinical trial on albumin replacement therapy in septic shock. The inclusion criterion regarding serum lactate concentration was amended to specify a higher threshold, aligning with contemporary definitions of septic shock.

Background

Accurate methodology in clinical trials is crucial for ensuring valid results and guiding treatment protocols. The correction of the inclusion criterion in the albumin therapy trial is significant as it reflects adherence to updated clinical definitions and guidelines for septic shock management. This topic is particularly relevant given the ongoing debate regarding the role of albumin in resuscitation strategies for septic patients.

Data Highlights

No numerical data is presented in the correction notice.

Key Findings

• The inclusion criterion for serum lactate concentration was corrected to 'higher than 18 mg/dL'.
• The corrected criterion aligns with the Sepsis-3 definition of septic shock.
• The Surviving Sepsis Campaign guidelines recommend crystalloids as first-line therapy, with albumin reserved for specific cases.
• Recent trials, including the ARISS trial, found no significant mortality benefit from albumin in septic shock.
• Prior studies, such as ALBIOS, also indicated no survival advantage from adding albumin to fluid resuscitation.

Clinical Implications

Highlight how the correction may influence clinical decision-making regarding albumin use.

Conclusion

Reinforce the need for continued research on albumin in septic shock management.

Related Resources & Content

1. VanderWeele, T., Li, J., JAMA Network Open, 2026 -- Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial
2. Surviving Sepsis Campaign Adult Guidelines | SCCM, 2026 -- Guidelines and Resources
3. JAMA Network Open, 2026 -- Error in Methods
4. American Journal of Epidemiology — Erratum Regarding Basic Sensitivity Analysis for Differential Measurement Errors
5. Open Forum Infectious Diseases — Amendment to: Effectiveness of Unstimulated Interferon-Gamma in Cerebrospinal Fluid (IRISA-TB) as an Immediate Diagnostic Tool for Tuberculous Meningitis in Resource-Limited, Tuberculosis-Prevalent Areas
6. The Journal of Infectious Diseases — Erratum: Monocytes and Macrophages as Targets of SARS-CoV-2: Insights into Immunoparalysis in COVID-19
7. Surviving Sepsis Campaign Adult Guidelines | SCCM
8. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial | Critical Care Medicine | JAMA Network Open | JAMA Network
9. Frontiers | Fluid resuscitation in adults with severe infection and sepsis: a systematic review and network meta-analysis